Zeng L et al. First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer. Med. 2024 Mar.
[5]AssessinganOralEGFRInhibitor,YK-209AinPatientsWhoHaveAdvancedNon-smallCellLungCancerWithEGFR(YK-029A-101) YK-029AasFirst-LineTreatmentVersusPlatinum-BasedChemotherapyforNon-SmallCellLungCancer(NSCLC)WithEGFR exon 20insertionMutations(YK-029A-301) YK-029AinTreatmentSideEffectsandTreatment-ICHGCP编辑...
GillAJ,AinsworthH,SolomonB,JohnT.EGFR exon 20insertionMutations:ClinicopathologicalCharacteristicsandTreatmentOutcomesinAdvancedNon-SmallCellLungCancer.ClinLungCancer.2021Nov;22(6):e859-e869.doi:10.1016/j.cllc.2021.04.009.Epub2021May16.PMID:34127383....
Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor receptor (gene were among the firstmutations to be identified as oncogenic drivers in non-small cell lung cancer (NSCLC). However, unlike the classicalL858R point mutation or exon 19 deletions, which ...
EGFR ex20ins的突变形式有很多,至今发现超过100种不同的突变形式,给治疗造成了很大难度。而且EGFR ex20ins会在其C螺旋结构附近形成一个“楔子”,形成刚性、不易弯曲的结构,将EGFR“锁定”在活性状态。目前常见的EGFR TKI很难有效地结合...
回溯“悟空6”(WU-KONG6)研究诞生之初,舒沃替尼正是针对这样的临床治疗难题,创新设计出了独特的柔性全新分子结构——苯胺基结构,可以有效抑制EGFR exon20ins突变,并且对野生型EGFR具有高选择性,突破了Exon20ins靶点“难成药”的魔咒。这项转化科学研究连同早期研究成果登上国际顶刊Cancer Discovery(影响因子:39.397)...
舒沃替尼成为EGFR exon20ins突变NSCLC患者靶向治疗最佳选择 EGFR 20号外显子插入(EGFR exon20ins)突变是仅次于EGFR敏感突变的第三大EGFR突变,其亚型繁多、恶性程度高、异质性强[1]。与EGFR敏感突变相比,EGFR exon20ins突变晚期NSCLC患者生存期更短、预后更差。而且传统的靶向治疗、化疗和免疫疗法在这类患者中的疗效...
9.Sabari JK, Shu CA, Park K, Leighl N, Mitchell P, Kim S, et al. Amivantamab in post-platinum EGFR Exon 20 insertion mutant non–small cell lung cancer [abstract OA04.04]. J Thorac Oncol.2021; 16: S108. 11.Zhou C, Ramalingam S, Li B, Fang J, Kim TM, Kim S, et al. ...
EGFR ex20ins的突变形式有很多,至今发现超过100种不同的突变形式,给治疗造成了很大难度。而且EGFR ex20ins会在其C螺旋结构附近形成一个“楔子”,形成刚性、不易弯曲的结构,将EGFR“锁定”在活性状态。目前常见的EGFR TKI很难有效地结合到20号外显子编码的结构域上。一项发表在《肺癌》(Lung Cancer)杂志上的真实...
[2] Pan B, Liang J, Shi H, et al. Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer. Thorac Cancer. 2023 Oct 5. [3] Girard N, Minchom A, Ou SI, Gadgeel SM, Trigo J, Viteri S, et al. Comparative clinical out...